NASDAQ: CERS
Cerus Corp Stock Forecast, Predictions & Price Target

Analyst price target for CERS

Based on 1 analyst offering 12 month price targets for Cerus Corp

Min Forecast
$4.00+48.15%
Avg Forecast
$4.00+48.15%
Max Forecast
$4.00+48.15%

Should I buy or sell CERS stock?

Based on 1 analyst offering ratings for Cerus Corp.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Buy" agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their CERS stock forecasts and price targets.

CERS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-01

1 of 1

Forecast return on equity

Is CERS forecast to generate an efficient return?

Company
30.25%
Industry
16.96%
Market
151.1%
CERS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CERS forecast to generate an efficient return on assets?

Company
9.17%
Industry
12.63%
CERS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CERS earnings per share forecast

What is CERS's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.05
Avg 2 year Forecast
-$0.03
Avg 3 year Forecast
$0.10

CERS revenue forecast

What is CERS's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$257.8M+5.3%
Avg 2 year Forecast
$279.7M+14.22%
Avg 3 year Forecast
$318.2M+29.98%
CERS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CERS revenue growth forecast

How is CERS forecast to perform vs Medical Devices companies and vs the US market?

Company
7.83%
Industry
8.82%
Market
16.71%
CERS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CERS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CERS vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
CERS$2.70$4.00+48.15%Strong Buy
NPCE$15.85$20.67+30.39%Strong Buy
TCMD$24.26$39.33+62.13%Strong Buy
BWAY$14.89$15.00+0.74%Buy
OFIX$12.09$17.25+42.68%Strong Buy

Cerus Stock Forecast FAQ

Is Cerus Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CERS) stock is to Strong Buy CERS stock.

Out of 1 analyst, 1 (100%) are recommending CERS as a Strong Buy, 0 (0%) are recommending CERS as a Buy, 0 (0%) are recommending CERS as a Hold, 0 (0%) are recommending CERS as a Sell, and 0 (0%) are recommending CERS as a Strong Sell.

If you're new to stock investing, here's how to buy Cerus stock.

What is CERS's earnings growth forecast for 2026-2028?

(NASDAQ: CERS) Cerus's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 30.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.16%.

Cerus's earnings in 2026 is -$9,550,000.On average, 5 Wall Street analysts forecast CERS's earnings for 2026 to be -$10,900,072, with the lowest CERS earnings forecast at -$19,636,159, and the highest CERS earnings forecast at -$4,207,748. On average, 5 Wall Street analysts forecast CERS's earnings for 2027 to be -$6,131,291, with the lowest CERS earnings forecast at -$17,672,544, and the highest CERS earnings forecast at $6,311,623.

In 2028, CERS is forecast to generate $20,437,635 in earnings, with the lowest earnings forecast at $19,636,159 and the highest earnings forecast at $21,038,742.

What is CERS's revenue growth forecast for 2026-2028?

(NASDAQ: CERS) Cerus's forecast annual revenue growth rate of 7.83% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.82%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.71%.

Cerus's revenue in 2026 is $244,838,000.On average, 5 Wall Street analysts forecast CERS's revenue for 2026 to be $51,659,128,877, with the lowest CERS revenue forecast at $49,246,686,430, and the highest CERS revenue forecast at $53,606,715,304. On average, 5 Wall Street analysts forecast CERS's revenue for 2027 to be $56,033,183,579, with the lowest CERS revenue forecast at $52,723,088,129, and the highest CERS revenue forecast at $59,329,253,201.

In 2028, CERS is forecast to generate $63,765,422,286 in revenue, with the lowest revenue forecast at $61,264,817,490 and the highest revenue forecast at $65,640,875,882.

What is CERS's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: CERS) forecast ROA is 9.17%, which is lower than the forecast US Medical Devices industry average of 12.63%.

What is CERS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CERS price target, the average CERS price target is $4.00, with the highest CERS stock price forecast at $4.00 and the lowest CERS stock price forecast at $4.00.

The Wall Street analyst predicted that Cerus's share price could reach $4.00 by May 1, 2027. The average Cerus stock price prediction forecasts a potential upside of 48.15% from the current CERS share price of $2.70.

What is CERS's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CERS) Cerus's current Earnings Per Share (EPS) is -$0.05. On average, analysts forecast that CERS's EPS will be -$0.05 for 2026, with the lowest EPS forecast at -$0.10, and the highest EPS forecast at -$0.02. On average, analysts forecast that CERS's EPS will be -$0.03 for 2027, with the lowest EPS forecast at -$0.09, and the highest EPS forecast at $0.03. In 2028, CERS's EPS is forecast to hit $0.10 (min: $0.10, max: $0.11).

What is CERS's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: CERS) forecast ROE is 30.25%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.